Tuesday, October 10, 2017


AXSM Axsome Therapeutics, Inc. gains 15% Oct 10, 2017

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of complex regional pain syndrome, knee osteoarthritis, and chronic low back pain; and AXS-05 that is in Phase III trial for the treatment of resistant depression and agitation in patients with Alzheimer's disease. The company is also developing AXS-06 for the treatment of chronic pain disorders. Axsome Therapeutics, Inc. was founded in 2012 and is based in New York, New York.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive